Cancer RPM Platform

• Cancer RPM Platforms are digital systems that continuously monitor oncology patients remotely through integrated sensor, survey, and clinical data.
• They employ advanced computational modeling, AI-driven analytics, and federated learning to enable real-time risk prediction and early intervention.
• These platforms ensure robust privacy, security, and seamless workflow integration, optimizing resource allocation across the cancer care continuum.

A Cancer Remote Patient Monitoring (RPM) Platform is a digital system designed to continuously assess, triage, and inform care for oncology patients outside the hospital setting using real-time or near-real-time multi-modal data, computational modeling, and AI-driven analytics. These platforms integrate structured and unstructured patient-reported outcomes, sensor data, clinical events, and predictive algorithms to mitigate treatment risks, enable early intervention, and optimize resource allocation across the cancer care continuum.

1. Architectural Frameworks and Core Components

Cancer RPM platforms are highly modular, encompassing patient-facing interfaces, backend data processing, clinical decision support layers, and integration with existing health IT ecosystems.

• Data Acquisition Layer: RPM platforms collect multi-modal data streams, including structured surveys, clinical event logs, wearable sensor telemetry (e.g., heart rate, activity), and patient voice/text inputs. Examples include HALO-X, which ingests 5-minute epoch sensor data, daily surveys (e.g., QoR-15), and clinical events via mobile and wearable devices (Liu et al., 30 Nov 2025), and RECOVER, which captures spoken symptom reports via Alexa Echo Dot (Yang et al., 9 Feb 2025).
• Backend Infrastructure: Core backend components include RESTful API or message-driven orchestration (Flask, OpenAI Azure), databases (PostgreSQL/SQLite, InfluxDB, document DBs), and data-processing pipelines (ETL for token sequences, normalization, feature extraction) (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025).
• AI and Analytics Modules: These feature information extraction (LLMs for logs-to-symptom mapping), summarization engines, time-series prediction (LSTM/Transformer-based risk forecasting), and federated analytics (e.g., QUALITOP's FedAvg across institutional silos) (Yang et al., 9 Feb 2025, Raheem et al., 10 Oct 2025).
• Clinical Dashboard and Alert Layer: Real-time web dashboards visualize patient status, risk trajectories, key symptoms (color-coded, Likert-scale overlays), and support multi-modal alerting (SMS/email, EHR integration). RECOVER, for instance, presents LLM-generated summaries and escalation flags for clinician review (Yang et al., 9 Feb 2025); HALO-X visualizes near-real-time risk trajectories with feature importances (Liu et al., 30 Nov 2025).
• Security and Privacy Controls: Platforms enforce HIPAA/GDPR compliance, role-based access, data encryption, and federated learning to avoid centralizing raw patient data (Yang et al., 9 Feb 2025, Raheem et al., 10 Oct 2025).

2. Data Modalities, Preprocessing, and Feature Engineering

Cancer RPM data are heterogeneous, asynchronous, and often incomplete, requiring advanced preprocessing and feature modeling to enable robust prediction and interpretation.

• Sensor Data: Includes time-resolved heart rate (HR), step counts, and device non-wear metrics. HALO-X processes these via missingness tokens (e.g., $m_{wear\%}(t)$, $m_{absence}(t)$) to retain temporal fidelity without artificial imputation (Liu et al., 30 Nov 2025).
• Patient-Reported Outcomes (PROs): Structured surveys (QoR-15, wellness check-ins, symptom checklists) and unstructured conversational logs (voice/text) capture subjective symptomatology and patient status (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025).
• Clinical Events: Treatment changes, admissions, dose modifications, and key interventions are timestamped and contextualized for dynamic risk modeling (Liu et al., 30 Nov 2025, Raheem et al., 10 Oct 2025).
• Data Normalization and Tokenization: Continuous variables are z-score normalized; categorical features (event types, device IDs) are one-hot encoded; time intervals are embedded (sinusoidal, time2vec) to retain event sequencing (Liu et al., 30 Nov 2025).
• Handling Missingness and Asynchrony: Platform models (HALO-X, RECOVER) avoid forced resampling/imputation in favor of native timestamp tokenization and explicit encoding of missingness (Liu et al., 30 Nov 2025, Yang et al., 9 Feb 2025).

3. Machine Learning, Modeling, and Clinical Decision Support

Cancer RPM platforms employ advanced machine learning methods for symptom triage, risk prediction, and personalized care recommendations.

• Transformer-based Models: HALO-X utilizes a multi-modal transformer to fuse demographic, sensor, survey, and clinical event streams as timestamped tokens, enabling real-time risk scoring for adverse events ($\hat{y} = \sigma(W_rz + b_r)$, binary cross-entropy loss) (Liu et al., 30 Nov 2025).
• LLM-powered Symptom Extraction: RECOVER leverages GPT-4o (Azure OpenAI) for structured extraction ($x_t = f_{extract}(c_t)$), real-time triage ($alert_t = 1$ if $s_{i,t} \geq \tau_i$), and explainable conversation flow, enforcing guideline adherence via prompt engineering (Yang et al., 9 Feb 2025).
• Federated Learning: QUALITOP's platform supports collaborative model training (FedAvg) without data centralization, minimizing $F(w) = \sum_{k=1}^K p_k F_k(w)$ and aggregating local updates via secure transmission ($w_{t+1} = \sum_{k=1}^K \frac{n_k}{\sum_j n_j} w_k$) (Raheem et al., 10 Oct 2025).
• Model Evaluation: Performance is quantified via accuracy, AUROC, and setup-specific metrics (e.g., symptom identification, event anticipation); HALO-X reports accuracy of 83.9% and AUROC of 0.70 (Liu et al., 30 Nov 2025), while RECOVER's SUS usability scores are high for both dashboard and CA modules (Yang et al., 9 Feb 2025). QUALITOP demonstrates federated prediction accuracies of 70–90% for treatment and adverse events (Raheem et al., 10 Oct 2025).

4. Interface Design, Workflow Integration, and Usability

Effective RPM deployment within clinical settings requires accessible interfaces, actionable visualizations, and seamless workflow embedding.

• Patient Interfaces: Voice-driven conversational agents (RECOVER), mobile apps (HALO-X), and web-based pedigree editors (Fam3PRO UI) collect high-fidelity, user-friendly inputs (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025, Chen et al., 27 Oct 2025).
• Clinician Dashboards: Visual tools surface triaged patient lists, symptom status (color-coded/metric overlays), LLM-generated summaries, and actionable report detail panels. Interaction models allow for annotation, override, and task management (review status, severity adjustment) (Yang et al., 9 Feb 2025).
• Workflow Integration: Multiple platforms support EHR embedding (SMART on FHIR, Epic MyChart), HL7 FHIR resource export/import, and role-based access tailored to local regulatory context (Yang et al., 9 Feb 2025, Chen et al., 27 Oct 2025).
• Usability Metrics: RECOVER's pilot yielded dashboard SUS_D = 93.75 ± 5.20, and CA SUS_C = 85 ± 6.10, with clinician-validated rapid task completion (patient location 0:32 min, interpretation 1:42 min) (Yang et al., 9 Feb 2025). Usability surveys in QUALITOP demonstrated high GUI satisfaction (Raheem et al., 10 Oct 2025).

5. Privacy, Security, and Responsible AI

Given the sensitivity of oncology data, cancer RPM platforms implement multi-layered privacy and security controls and address biases and AI explainability.

• Federated and Decentralized Processing: QUALITOP and similar architectures (Virtual Data Lake, federated aggregation) prevent transfer of raw patient data beyond institutional firewalls, instead transmitting aggregated or encrypted model updates (Raheem et al., 10 Oct 2025).
• Access Controls and Data Encryption: Systems enforce RBAC, MFA, encrypted communications (TLS/HTTPS, AES-256), and encrypted patient identifier storage in backend databases (Yang et al., 9 Feb 2025, Raheem et al., 10 Oct 2025).
• Compliance and Auditability: GDPR/HIPAA compliance is paramount, with regular security reviews, DTA agreements, institutional audits, and optional immutable audit trails using blockchain approaches in planned next phases (Raheem et al., 10 Oct 2025).
• Responsible AI Practices: RECOVER employs allowlists and denylists to constrain LLM output to non-diagnostic, neutral language, integrates disclaimers (“not a doctor”), and requires human-in-the-loop review of flagged alerts. All logs are subject to periodic peer-review and post-hoc safety analysis to mitigate hallucinations and misclassification (Yang et al., 9 Feb 2025).

6. Extensibility, Performance, and Future Directions

Broad deployment requires adaptability to new data sources, disease domains, and evolving care paradigms.

• Multi-Modal and Cross-Platform Integration: RECOVER and HALO-X are actively incorporating wearable biosensors, EHR vitals, lab results, and imaging summaries for more holistic risk models (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025). Fusion strategies (e.g., $z_t = [x_t; \bar{v}_t; w_t]$) support extending transformer architectures to these additional modalities.
• Generalizability to Other Cancer Types and Therapies: Data schemas, guideline prompts, and symptom checklists can be templated or abstracted for other cancer sites (breast, prostate, hematologic, etc.), with protocol adaptation based on disease course and treatment modalities (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025).
• Personalization and Adaptive Protocols: Dynamic prompt generation, individualized risk scoring (e.g., risk-driven question schedules $f(t') \propto r_t = g(x_t)$), and EHR context-aware nudges enable patient-specific monitoring strategies (Yang et al., 9 Feb 2025).
• Scalability and Distributed Analytics: Federated platforms (QUALITOP) allow new institutional participants to join with only API and ontology-level integration, and performance scales linearly with number of clinical sites (Raheem et al., 10 Oct 2025).
• Clinical Impact and Validation: Ongoing and future studies focus on real-world deployment, randomized trials for clinical outcomes (hospitalization reduction, survival), and further integration into standard oncology care pathways (Liu et al., 30 Nov 2025, Raheem et al., 10 Oct 2025).

Cancer RPM platforms, exemplified by RECOVER, HALO-X, QUALITOP, and Fam3PRO UI, are architected to provide scalable, privacy-preserving, and clinically actionable infrastructure for the remote management of oncology patients. Their technical rigor, commitment to responsible AI use, and demonstrated real-world feasibility chart a path for continued expansion across oncology practice (Yang et al., 9 Feb 2025, Liu et al., 30 Nov 2025, Raheem et al., 10 Oct 2025, Chen et al., 27 Oct 2025).